Roche is at the forefront of efforts to combat HIV and AIDS, committed for 15 years to ground-breaking research and development of award-winning new drugs and diagnostic technology, to provide tailored treatment solutions and an improved standard of care worldwide for those people living with HIV.

INNOVATING HIV CARE-DEVELOPMENT OF NOVEL PHARMACEUTICALS AND DIAGNOSTICS STATEGIES TO ADDRESS KEY UNMET MEDICAL NEEDS IN HIV/AIDS 2003 FUZEON® antiviral activity maintained through 48 weeks EU regulatory filing for Roche's new VIRACEPT® 625 mg formulation FUZEON® receives European approval FUZEON® receives US approval COBAS AMPLICOR HIV-1 MONITOR™ Test Version 1.5 (automated version) receives US approval Regulatory filing for the first HIV fusion inhibitor, FUZEON® (enfuvirtide) 2002 Roche licences in a new-generation, preclinical NNRTI from Medivir   Entry into humans for Roche’s new protease inhibitor R944 EU approval for boosted saquinavir/ritonavir 1000/100 mg bid AMPLICOR HIV-1 MONITOR® Test Version 1.5 receives US approval (can additionally detect and quantify non-B HIV subtypes) 2001 VALCYTE® (valganciclovir) receives US and EU approval for treatment of AIDS-related CMV retinitis Phase III studies begin with the first HIV fusion inhibitor 2000 Roche presents data on the first HIV resistance assay using micro-array chip technology   1999 AMPLICOR HIV-1 MONITOR® Ultra Sensitive Method approved (measures down to 50 HIV RNA copies/ml) Roche initiates research and development collaboration with Trimeris Inc on inhibition of HIV fusion               VIRACEPT® (nelfinavir) approved in EU 1998   1997 Approval for new formulation of saquinavir: FORTOVASE® AMPLICOR HIV-1 MONITOR® Test approved (measures down to 400 HIV RNA copies/ml) 1996 1995 INVIRASE® (saquinavir), the first protease inhibitor, introduced CYMEVENE®/CYTOVENE® (ganciclovir) capsules approved for treatment of CMV retinitis in HIV 1994 1992 HIVID® (zalcitabine) approved Qualitative AMPLICOR® PCR test approved IV ganciclovir approved for HIV induction therapy 1989     1987 First Roche HIV antibody test introduced Roche initiates protease project 1986 ROFERON-A® (interferon alfa-2a) approved for Kaposi’s sarcoma